ErbB2 diagnostics in breast cancer - An update;Aktuelles zur ErbB2-Diagnostik beim Mammakarzinom

Pathologe

Volumn 30, Issue 2, 2009, Pages 147-155

  Ruschoff J ^a   Nagelmeier, I ^a   Hofmann, M ^a   Henkel, Th ^b   Stoss, O ^b  

^a Pathologie Nordhessen   (Germany)

^b TARGOS Molecular Pathology GmbH   (Germany)

Author keywords

CISH; ErbB2 Her 2 neu receptor; FISH; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ARTICLE; BREAST CARCINOMA; CHROMOSOME 17; CLINICAL PRACTICE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE NUMBER; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE;

BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS;

EID: 63349098813     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00292-009-1126-3     Document Type: Article

References (39)

1. Boecker W (ed) (2006) Preneoplasia of the breast. A new conceptual approach to proliferative breast disease. Saunders Elsevier, München
2. Bilous 2003 Mod Pathol 16 173
3. Chibon F, de Mascarel I, Sierankowski G et al (2008) Prediction of HER2 gene status in Her2 2+ invasive breast cancer: A study of 108 cases comparing ASCO/CAP and FDA recommendations. Mod Pathol [Epub ahead of print]
4. Dal 2006 Mol Cancer Ther 10 2572
5. Dendukuri 2007 CMAJ 176 1429
6. Dowsett M, Procter M, McCaskill-Stevens W et al (2009) Disease-free-survival according to degree of Her2 amplification for patients treated with adjuvant chemotherapy with/without 1-year's trastuzumab in the HERA trial. JCO (accepted)
7. Giltnane 2008 Arch Pathol Lab Med 132 1635
8. Gown 2008 Mod Pathol 21 1271
9. Hanna 2007 Curr Oncol Rep 14 149
10. Harari 2000 Oncogene 19 6102
11. Hofmann 2008 J Clin Pathol 61 89
12. Laakso 2006 J Pathol 210 3
13. Latta 2002 Mod Pathol 15 1318
14. Leary AF, Hanna W, Penault-Llorca F et al (2009) Value and limitations of measuring serum HER2 extracellular domain (ECD) in breast cancer patients. JCO (accepted)
15. Lee-Hoeflich 2008 Cancer Res 68 5878
16. Ma 2005 Clin Cancer Res 11 4393
17. Neubauer 2008 Anticancer Res 28 1797
18. Neyt 2006 Ann Oncol 17 381
19. Nitta 2008 Diagn Pathol 3 41
20. Omeroglu 2008 Mod Pathol 21 48A
21. Paik 2008 N Engl J Med 358 1409
22. Penault-Llorca F, MacGrogan G, Jacquemier J et al (2009) High concordance for HER2 testing at French histopathology centers for patients with metastatic breast cancer: The FISH 2002 study. Br J Cancer (submitted)
23. Perez 2006 J Clin Oncol 24 3032
24. Persons 2006 Arch Pathol Lab Med 130 325
25. Piccart-Gebhart 2005 N Engl J Med 353 1659
26. Press 2008 Clin Cancer Res 14 7861
27. Press 2005 Clin Cancer Res 11 6598
28. Rastelli 2008 Tumori 94 370
29. Santa 2008 Semin Diagn Pathol 25 231
30. Sassen 2008 Breast Cancer Res 10 R2
31. Scaltriti 2007 J Natl Cancer Inst 99 628
32. Stemke-Hale 2008 Cancer Res 68 6084
33. Striebel 2008 Am J Clin Pathol 129 383
34. Tapia 2007 Breast Cancer Res 9 R31
35. Umemura 2008 Am J Clin Pathol 130 883
36. Vanden 2008 J Clin Oncol 26 4869
37. van 2007 Breast Cancer Res 9 R68
38. Wasielewski 2008 Virchows Arch 453 537
39. Wolff 2007 J Clin Oncol 25 118